GlassScriptPhysician profile
Edward D Ellison
NPI 1346375235
$7,398.82
in general payments reported to CMS, 2019-2025
46 companies · $1,628 in 2025
The $1,628 reported for 2025 was more than what 75% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,102 · 2020: $331 · 2021: $855 · 2022: $1,029 · 2023: $1,119 · 2024: $1,335 · 2025: $1,628.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,849 · Education: $232.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,849.46 |
| Education | $232.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $1,397.92 | 2019-2025 | Xtandi, Myrbetriq |
| Janssen Biotech, INC. | $721.29 | 2019-2025 | Erleada, Akeega |
| Dendreon Pharmaceuticals LLC | $562.36 | 2019-2025 | Provenge |
| Sumitomo Pharma America, INC. | $466.02 | 2023-2025 | Gemtesa, Orgovyx |
| Boston Scientific Corporation | $354.98 | 2019-2025 | Rezum Generator, Lumenis Pulse 120h, Axonics |
| Pfizer INC. | $329.64 | 2019-2025 | |
| Abbvie INC. | $309.44 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $302.87 | 2019-2025 | Yonsa |
| Bayer Healthcare Pharmaceuticals INC. | $298.14 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $186.01 | 2021-2024 | Lynparza, Keytruda, Welireg |
| Myriad Genetic Laboratories, INC. | $157.47 | 2021-2024 | Prolaris, Myrisk |
| Endo Pharmaceuticals INC. | $138.45 | 2020-2022 | |
| Ferring Pharmaceuticals INC. | $137.27 | 2019-2025 | Adstiladrin |
| Accord Healthcare, INC. | $137.18 | 2023-2025 | |
| Urogen Pharma, INC. | $111.20 | 2020-2025 | Jelmyto |
Show all 46 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Innovation Technologies INC | $109.23 | 2021-2022 | |
| Myovant Sciences INC. | $96.94 | 2021-2022 | |
| Verity Pharmaceuticals INC. | $92.67 | 2022-2024 | Trelstar |
| Astrazeneca Pharmaceuticals LP | $89.61 | 2020-2024 | |
| Allergan, INC. | $89.04 | 2019-2021 | |
| Endo USA, INC. | $86.34 | 2024-2025 | Xiaflex |
| Urovant Sciences INC | $85.07 | 2021-2022 | |
| Olympus America INC. | $83.33 | 2021-2025 | Bovie, Soltive, Itind System |
| Immunitybio, INC. | $74.62 | 2024-2025 | |
| Tolmar Pharmaceuticals, INC. | $73.91 | 2019-2022 | |
| Tolmar, INC. | $72.68 | 2023-2024 | |
| Novartis Pharmaceuticals Corporation | $72.42 | 2019-2025 | |
| Bluewind Medical | $66.45 | 2025 | Revi |
| Coloplast Corp | $64.81 | 2021-2022 | |
| Blue Earth Diagnostics | $60.34 | 2019-2024 | |
| Laborie Medical Technologies Corp. | $55.64 | 2023-2024 | Optilume Bph Drug Coated Balloon Catheter |
| Amgen INC. | $53.44 | 2019 | |
| Travere Therapeutics, INC. | $51.49 | 2019-2022 | |
| Progenics Pharmaceuticals, INC. | $49.65 | 2024 | |
| Axonics, INC. | $47.18 | 2022-2023 | Axonics |
| Telix Pharmaceuticals | $42.20 | 2023-2024 | Illuccix |
| Baxter Healthcare | $38.53 | 2022 | |
| Foundation Medicine, INC. | $36.39 | 2022 | |
| Dornier Medtech America, INC | $34.89 | 2019 | |
| Caris Mpi, INC. | $33.52 | 2025 | Mi Cancer Seek |
| Antares Pharma, INC. | $32.42 | 2019-2022 | |
| Bk Medical Holding Company INC. | $24.82 | 2020 | |
| Cardinal Health 414 LLC | $22.51 | 2025 | |
| Ambu INC. | $22.40 | 2021 | |
| Profound Medical Corp. | $13.42 | 2022 | |
| Photocure INC | $12.62 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edward Ellison listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.